Mira Pharmaceuticals, INC Form 4 insider transactions

MIRA Pharmaceuticals CEO Erez Aminov received a grant of 83,500 fully vested restricted stock units, convertible to common stock.

MIRA Pharmaceuticals Director Denil Nanji Shekhat acquired 22,378 shares of common stock as compensation for the acquisition of SKNY Pharmaceuticals, Inc.

MIRA Pharmaceuticals CEO Erez Aminov acquired 2,685,456 restricted common shares as compensation for the company's acquisition of SKNY Pharmaceuticals, Inc.

MIRA Pharmaceuticals' CEO, Erez Aminov, had 300,000 stock options repriced to an exercise price of $1.38, aligning with the recent closing stock price.

MIRA Pharmaceuticals CEO Erez Aminov acquired 62,500 shares of common stock at $1.37 per share, increasing his direct beneficial ownership to 844,700 shares.

Director Matthew Whalen of Mira Pharmaceuticals was granted 25,000 stock options with a vesting schedule over one year.

Mira Pharmaceuticals has granted 25,000 stock options to Edward MacPherson, vesting in two equal tranches over the next year.

Michelle Yanez, CFO of Mira Pharmaceuticals, was granted 150,000 stock options with a $1.19 exercise price.

Mira Pharmaceuticals' CEO, Erez Aminov, received 2,000,000 stock options and 500,000 restricted stock units, vesting in two tranches.

Director Denil Nanji Shekhat of Mira Pharmaceuticals acquired 50,000 stock options with an exercise price of $1.19 on December 9, 2024.

Matthew Paul Del Giudice, an executive at Mira Pharmaceuticals, was granted 25,000 stock options with a $1.19 exercise price.

Mira Pharmaceuticals CEO, Erez Aminov, sold a total of 100,000 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

Brian McNulty, a director and 10% owner of MIRA Pharmaceuticals, sold 200,000 shares of common stock at $1.96 per share and updated his power of attorney.

Director Denil Nanji Shekhat of Mira Pharmaceuticals, Inc. receives stock options as part of a consulting agreement.

Erez Aminov, CEO of Mira Pharmaceuticals, was granted 379,000 stock options on May 28, 2024, which vested immediately.

Erez Aminov, CEO of Mira Pharmaceuticals, recently acquired additional shares of the company's common stock through a series of transactions on May 21, 2024.

Erez Aminov, CEO of Mira Pharmaceuticals, was granted 300,000 incentive stock options with an exercise price of $1.15 on March 26, 2024.

Director Denil Nanji Shekhat acquired nonqualified stock options in Mira Pharmaceuticals on March 25, 2024.

Michelle Yanez, CFO of Mira Pharmaceuticals, was granted incentive stock options to purchase 150,000 shares of common stock at an exercise price of $1.15.

Michael Jerman, a director at Mira Pharmaceuticals, acquired 50,000 nonqualified stock options on March 25, 2024, with half vesting immediately and the remainder vesting in one year.

Director Edward Clouston MacPherson acquired nonqualified stock options in Mira Pharmaceuticals, with a portion vesting immediately.

Matthew Paul Del Giudice, a director of Mira Pharmaceuticals, acquired nonqualified stock options on March 25, 2024.